RESULTS	Patients receiving postprotocol therapy including a tyrosine kinase inhibitor had longer median OS ( bevacizumab plus IFN arm : 38.6 months ; IFN plus placebo arm : 33.6 months ; HR = 0.80 ; 95 % CI , 0.56 to 1.13 ) .\